1. Introduction
===============

1.1. Description of the condition
---------------------------------

Because of the aging group, this fraction epidemic is predicted to exponentially escalate by 2050.^\[[@R1]\]^ Sarcopenia (SP) and osteoporosis (OP) are 2 age-related chronic diseases. SP is diagnosed as the decline in skeletal muscle mass and function, which has serious influence on patient\'s activities and diet. OP is defined as a systemic bone disease characterized by age-related fracture risk. Loss of bone and muscle strength combine into a single diagnosis of "sarco-osteopenia" (SOP).^\[[@R2]\]^ SOP is a major disease for elderly people, which is considered as a higher risk for falls and fractures.^\[[@R2]--[@R4]\]^ Among elderly people, SOP is associated with significant morbidity and mortality as well as a decline in the quality of life. After 50 years, muscle mass decreases by 0.5% to 2% annually and muscle strength by 1.5% to 3%.^\[[@R5]\]^ This decrease is greater in the sedentary population and in males, in whom a prevalence of double resistance is found. Also, for women, bone mass begins to decrease by 0.5% from 30 years with a rapid point decrease in postmenopausal women, this decrease being stable in men.^\[[@R6],[@R7]\]^ These changes together with multiple contributing factors, such as sedentary lifestyle, malnutrition, chronic diseases, and some pharmacological treatments, finally producing OP and SP, even SOP.

1.2. Description of the intervention
------------------------------------

As for treatments for SOP, new pharmacological treatments are developed for the management of low body mass index (BMI) and SP.^\[[@R8]\]^ Myostatin (inhibitor of muscle development) is one of the therapeutic targets that are currently studied.^\[[@R9]\]^ A study showed that administration of ACVR2B-Fc (myostatin receptor recombinant protein) resulted in an increase in lean body mass and markers of bone formation in postmenopausal women.^\[[@R10]\]^ The antibody LY2495655 has been associated with a moderate increase in muscle mass and strength.^\[[@R11]\]^ Other pharmacological therapies such as testosterone, inhibitors of angiotensin-converting enzyme, ghrelin, growth hormone, and insulin-like factor 1 have also been evaluated to treat both OP and SP, but no clear evidence of their benefits has been found so far.^\[[@R12]\]^ Chinese medicine has good clinical efficacy in the treatment of OP. And Xianling gubao is the well-known Chinese patent medicine. The recipe is based on the modern prescriptions of the Miao people. A new type of national medicine was developed. The prescription was collected, sorted, and screened by a famous orthopedics expert, Professor Shi Guangda, and eventually consisted of 9 Chinese herbs, such as epimedium, psoralen, psoralen, Radix Rehmanniae, Salvia miltiorrhiza, and Zhimu, which are mainly used in the treatment of OP, fracture, osteoarthritis, aseptic necrosis, etc. There are a lot of literatures showing that Xianling Gubao capsule (XLGBC) has a good effect on the treatment of bone diseases.^\[[@R13]--[@R15]\]^ Thus, the purpose of this review is to summarize clinical researches on XLGBC for SOP and findings of this review will be reliable within evidence of clinical studies.

2. Methods and analysis
=======================

2.1. Study registration
-----------------------

The protocol has been registered on the International Prospective Register of Systematic Reviews (PROSPERO) (registration number, CRD42019128223) basing on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement guidelines (Fig. [1](#F1){ref-type="fig"}).
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2.2. Eligibility criteria
-------------------------

### 2.2.1. Types of studies

Regardless of the blind method and language, randomized controlled trials that evaluate the effect of XLGBC on patients with SOP will be included. The following types of studies will be excluded: nonclinical researches, including animal experiments, reviews, conference papers, and so on; duplicate publications; literatures lacking data that are needed for our study; studies that have no diagnostic criteria or efficacy criteria; and the baseline data are significantly inconsistent.

### 2.2.2. Types of participants

This study will include patients who simultaneously meet the diagnosis of OP and SP.

### 2.2.3. Types of interventions

The control group will comprise patients receiving no treatment, placebo, or routine treatment. The intervention group will include XLGBC based on routine regimens as intervention measures.

### 2.2.4. Types of outcomes measures

The primary outcomes will include BMD, SMI, handgrip strength, and gait speed.

The secondary outcomes will include short physical performance battery score (SPPBS), balance ability, pain, and adverse events.

2.3. Search strategy
--------------------

### 2.3.1. Electronic searches

Seven databases including Cochrane Library, PubMed, Embase, Chinese National Knowledge Infrastructure (CNKI), Chinese Scientific Journal Database (VIP), Chinese Biomedical and Medical Database (CBM), and Wanfang Database will be searched with a time span from their inception to March 2018. The search strategy in PubMed database is as follows: "Xianling Gubao Capsule" AND "Sarco-Osteopenia" or ("sarcopenia" and "osteoporosis"). Chinese translation of the above retrieval strategy will be used for Chinese database search.

### 2.3.2. Other resources

In order to obtain the potential nonelectronic literatures, relevant magazines and medical journals will also be filtered for further search.

### 2.3.3. Study selection and data extraction

With the help of Endnote V.X7 (Columbia CP Ltd), 2 reviewers will carry out the first round of selection by preliminarily screening the title and abstract of the obtained articles. Duplicate publications, nonclinical researches, and irrelevant articles will be excluded. Another round of selection will be conducted through reading the full text of the documents to decide the final inclusions. Any disagreement will be settled by discussion the judgement of a third reviewer. The study selection procedure will be showed by a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart (Fig. [1](#F1){ref-type="fig"}). Microsoft Excel will be utilized for data extraction. Data including the following items, general information, trial characteristics, participants, interventions, and outcomes, will be collected in 5 spreadsheets, respectively.

### 2.3.4. Dealing with the missing data

If any article lacks the necessary data, we will contact authors of the article by the contact information we can get. If we fail in this way, the potential impact that the missing data would probably bring about will be analyzed in the discussion part.

### 2.3.5. Risk of bias in included studies

According to suggestions from Cochrane Handbook for Systematic Reviews of Interventions, risk of bias of each included trial will be assessed in the following aspects: random sequence generation, allocation concealment, implementation of the blind method, incomplete data, selective report, and other bias. Risk of bias will be evaluated as low, high, or unclear (unclear or unknown risk of bias).

2.4. Statistical analysis and data synthesis
--------------------------------------------

Meta-analysis of the included studies will be performed by statistical softwares, respectively (Stata 14.0 software (Canada, Statagroup) and Stata 12.0 software (Canada, Statagroup)). Mean difference (MD) or standard mean difference (SMD) will be used for continuous variables, and rate ratio (RR) will be chosen for dichotomous variables. Besides, 95% confidence intervals (95% CIs) for both variables will also be measured. As for data synthesis, the heterogeneity of each included studies will be assessed by *I*^2^ test statistics firstly. The evaluation criteria are as follow: *I*^*2*^ \< 25% means no significant heterogeneity, *I*^*2*^ = 25% to 50% indicates moderate heterogeneity, and *I*^*2*^ \> 50% represents strong heterogeneity. Then, basing on the *I*^*2*^ value, the random-effects model (*I*^*2*^ ≥ 50%, significant heterogeneity) or the fixed-effect model (*I*^*2*^ \< 50%, low heterogeneity) will be chosen.

2.5. Subgroup analysis and sensitivity analysis
-----------------------------------------------

Once heterogeneity appears significant (*I*^*2*^ ≥ 50%) and the trials included are adequate, we will perform subgroup analysis and sensitivity analysi**s** to seek the probable source of the heterogeneity, in consideration of different study characteristics, such as participants characteristics, sample size, interventions, controls, outcome measures, and so on.

2.6. Assessment of reporting bias
---------------------------------

When the number of the included studies exceeds 10, reporting bias will be assessed by funnel plots drawn through Egger regression test. Symmetry of funnel plots indicates no reporting bias. On the contrary, if the points of the funnel plot appear to be dispersed and asymmetrical, reporting bias is considered to be existent and the reliability is low.

2.7. Quality of evidence
------------------------

With the guidance of the Recommendations Assessment, Development, and Evaluation guideline, the quality of evidence will be evaluated by 2 reviewers. We will take into account limitations of the study, inconsistencies, indirect evidence, imprecision, and publication bias. Levels of evidence quality will be rated as high, moderate, low, or very low.

2.8. Ethics and dissemination
-----------------------------

Ethical approval will not be needed, as the data extracted for our study are derived from published literature and will not cause invasion of participant privacy. We aim to publish this systematic review, evaluating the effects of XLGBC on SOP.

3. Discussion
=============

Although currently in SOP drug research has made great progress, a common target for "muscle-osteoporosis" therapeutic drugs is still less, and the efficacy is not exact.^\[[@R16]\]^ The current treatments are single treatments for one of these conditions.^\[[@R17]\]^ May be beneficial to the muscles at the same time, and therefore extended to treat the muscles less serious. It mainly includes anabolic hormones, vitamin D, receptor agonists, and growth hormones.^\[[@R18]\]^

To the best of our knowledge, it will be the first systematic review and meta-analysis on XLGBC in the treatment of SOP. First, the results of this review will provide objective statistics for further researches on SOP. Second, the results will offer reliable references for clinicians and patients in the treatment of SOP with XLGBC. Third, the results may introduce an alternative therapy of SOP to policy makers to decrease the burden of public health.
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